Rigel Pharmaceuticals, Inc. (RIGL)
After hours:
| Previous close | 1.0500 |
| Open | 1.0600 |
| Bid | 1.0700 x 400 |
| Ask | 1.1000 x 1200 |
| Day's range | 1.0600 - 1.1100 |
| 52-week range | 0.7100 - 1.9600 |
| Volume | |
| Avg. volume | 1,511,170 |
| Market cap | 191.191M |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.57 |
ZacksRigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireRigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
ZacksSilence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
